逆转录病毒复制载体介导的基因治疗实现肿瘤复发的长期控制并诱导持久抗癌免疫
该研究在免疫缺陷宿主的人胶质瘤异种移植模型和免疫健全宿主的同源小鼠胶质瘤模型中,评估表达酵母胞嘧啶脱氨酶的肿瘤选择性逆转录病毒复制载体(RRV)Toca 511联合前药5-氟胞嘧啶的疗效机制。两种模型中单次注射复制载体后给予前药均获得长期生存获益;免疫健全模型中仅1-2个周期前药即实现肿瘤信号完全消失并长期无复发,且长期存活者排斥未感染胶质瘤细胞,CD4+ T细胞被证明起关键作用。结论支持该疗法通过前药转化介导的细胞减灭和诱导抗肿瘤免疫的双重机制发挥作用。
要点
- 在免疫缺陷和免疫健全胶质瘤模型中,单次注射RRV后给予前药均获得长期生存获益。
- 免疫缺陷模型中肿瘤反复复发,通过生物发光成像指导多周期前药给药可继续控制疾病负荷并实现长期生存。
- 免疫健全模型中仅1-2个周期前药即肿瘤信号完全消失,停药后无复发长期生存超过300天。
核心结论
- RRV介导的前药激活基因治疗通过前药转化介导的细胞减灭实现长期肿瘤控制,并诱导抗肿瘤免疫,双重机制共同贡献疗效。
研究设计与样本
- 研究在正位脑肿瘤模型中探究该方法的疗效机制,采用免疫缺陷宿主的人胶质瘤异种移植模型和免疫健全宿主的同源小鼠胶质瘤模型。
主要发现
- 两种模型中,单次注射复制载体后给予前药均获得长期生存获益。
- 免疫缺陷模型中肿瘤反复复发,但肿瘤生物发光成像使多周期前药给药得以定制安排,继续控制疾病负荷并实现长期生存。
- 免疫健全模型中仅1-2个周期前药后即观察到肿瘤信号完全消失,随后停药仍长期无复发生存超过300天。
- 长期存活者排斥未感染胶质瘤细胞的攻击,表明针对天然肿瘤抗原的免疫应答;免疫细胞清除显示CD4+ T细胞起关键作用。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prodrug-activator gene therapy with Toca 511, a tumor-selective retroviral replicating vector (RRV) encoding yeast cytosine deaminase, is being evaluated in recurrent high-grade glioma patients. Nonlytic retroviral infection leads to permanent integration of RRV into the cancer cell genome, converting infected cancer cell and progeny into stable vector producer cells, enabling ongoing transduction and viral persistence within tumors. Cytosine deaminase in infected tumor cells converts the antifungal prodrug 5-fluorocytosine into the anticancer drug 5-fluorouracil, mediating local tumor destruction without significant systemic adverse effects. METHODS: Here we investigated mechanisms underlying the therapeutic efficacy of this approach in orthotopic brain tumor models, employing both human glioma xenografts in immunodeficient hosts and syngeneic murine gliomas in immunocompetent hosts. RESULTS: In both models, a single injection of replicating vector followed by prodrug administration achieved long-term survival benefit. In the immunodeficient model, tumors recurred repeatedly, but bioluminescence imaging of tumors enabled tailored scheduling of multicycle prodrug administration, continued control of disease burden, and long-term survival. In the immunocompetent model, complete loss of tumor signal was observed after only 1-2 cycles of prodrug, followed by long-term survival without recurrence for >300 days despite discontinuation of prodrug. Long-term survivors rejected challenge with uninfected glioma cells, indicating immunological responses against native tumor antigens, and immune cell depletion showed a critical role for CD4+ T cells. CONCLUSION: These results support dual mechanisms of action contributing to the efficacy of RRV-mediated prodrug-activator gene therapy: long-term tumor control by prodrug conversion-mediated cytoreduction, and induction of antitumor immunity.
引用
- Hiraoka K, Inagaki A, Kato Y, et al. Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity. Neuro Oncol. 2017. PMID: 28387831. doi:10.1093/neuonc/nox038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。